These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23722626)

  • 1. Defining "innovativeness" in drug development: a systematic review.
    Kesselheim AS; Wang B; Avorn J
    Clin Pharmacol Ther; 2013 Sep; 94(3):336-48. PubMed ID: 23722626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2017 Jan; 101(1):8-12. PubMed ID: 27869291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using patent data to assess the value of pharmaceutical innovation.
    Kesselheim AS; Avorn J
    J Law Med Ethics; 2009; 37(2):176-83. PubMed ID: 19493065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The performance of China's biomedical innovation: a scientometric analysis.
    Tang X; Du J
    Sci China Life Sci; 2016 Oct; 59(10):1074-1082. PubMed ID: 27437700
    [No Abstract]   [Full Text] [Related]  

  • 6. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of drug development: a grim reality and a role for clinical pharmacology.
    Honig P; Lalonde R
    Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
    Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
    Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical research and development: what do we get for all that money?
    Light DW; Lexchin JR
    BMJ; 2012 Aug; 345():e4348. PubMed ID: 22872694
    [No Abstract]   [Full Text] [Related]  

  • 12. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 16. How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.
    Ward DJ; Slade A; Genus T; Martino OI; Stevens AJ
    BMJ Open; 2014 Oct; 4(10):e006235. PubMed ID: 25344485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Something new every day: defining innovation and innovativeness in drug therapy.
    Aronson JK
    J Ambul Care Manage; 2008; 31(1):65-8. PubMed ID: 18162799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
    Falagas ME; Fragoulis KN; Karydis I
    PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative drugs and vaccines in China, India and Brazil.
    Rezaie R; McGahan AM; Daar AS; Singer PA
    Nat Biotechnol; 2012 Oct; 30(10):923-6. PubMed ID: 23051806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.